中文 | English
Return
Total: 182 , 1/19
Show Home Prev Next End page: GO
Author:(Huixia LI)

1.Expression and significance of FOXC2, Vimentin and E-cadherin in colorectal adenocarcinoma

Dan LI ; Huixia ZHENG

Journal of Chinese Physician 2017;19(6):864-867

2.Effects of high glucose on phosphorylations of insulin signaling proteins in rat adipocytes

Huixia LIU ; Lirong LI

Chinese Journal of Endocrinology and Metabolism 2001;0(05):-

3.Problems and strategies for practice teaching of laboratory medicine under tense doctor-patient relationship

Keping CHEN ; Li LI ; Huixia LU

Chinese Journal of Medical Education Research 2014;13(11):1185-1188

4.The effects of pioglitazone on the Kupffer cells of nonalcoholic fatty liver disease in rats

Dan HE ; Lan LI ; Huixia LIU

Journal of Chinese Physician 2014;(7):886-890

5.Analysis of 962 ADR/ADE Cases of Mailuoning Injection

Wenwu LI ; Xudong XIA ; Huixia ZHANG

China Pharmacy 2005;0(24):-

6.Application of new cleaning process in instruments cleaning by automatic spray cleaning machine

Chaoying LI ; Jun SUN ; Huixia WANG

Chinese Journal of Practical Nursing 2008;24(24):58-

7.A study of correlation between insulin resistance and the clinical pathology characters in chronic hepatitis B patients

Bingyu LI ; Fusheng WANG ; Huixia LIU

Journal of Chinese Physician 2009;11(5):603-605

8.Effects of severe hyperglycaemia in pregnancy and early overfeeding on islet development and insulin resistance

Chanjuan ZENG ; Li ZHANG ; Huixia YANG

Chinese Journal of Obstetrics and Gynecology 2010;45(9):658-663

9.Clinical values of solution-focused therapy for caregivers of elderly patients with hip fractures

Huixia ZHANG ; Fengling LI ; Fuyan WANG

Chinese Journal of Practical Nursing 2017;33(20):1547-1551

10.Analysis of 58 Cases of ADR/ADE with Cardiac Damage Induced by Metranidazole

Li WANG ; Xiaojie ZHOU ; Huixia ZHANG

China Pharmacy 2016;27(26):3643-3645

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 182 , 1/19 Show Home Prev Next End page: GO